Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED | N.MMED.WA | N.MMED.WR

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > What is happening today?

<< Previous

Bullboard Posts

Next >>

Comment by MrVerbatim9800on Aug 18, 2022 10:26am

212 Views

Post# 34904612

RE:What is happening today?

Losses cut by nearly 1/3 ! That's awesome. New CEO that actually has drive and getting us out there again. Recognition that we need to increase our position for the listing etc..... Lot's of good news out there!

Not to mention that this industry is heating up again..... Even Netflix is onboard with thier new documentary about mushrooms/psychedelics and the benefits.......

V.